FreeTheAI

bioAffinity Technologies to Present Sputum Biomarker Research at CHEST 2026

BearishMedium impact
BIAF$3.51 −3.31%

bioAffinity Technologies, Inc. (BIAF) announced plans to present research on its investigational sputum-based test at the CHEST 2026 medical conference. The presentation will feature data showing the test can detect key cellular and soluble protein biomarkers linked to lung inflammation, including TSLP, CRLF2, IL4-Rα, and IL-5. These biomarkers are associated with drug targets for asthma and chronic obstructive pulmonary disease (COPD).

The research builds upon the company's CyPath Lung flow cytometry and artificial intelligence platform. By measuring specific inflammatory proteins in sputum, the technology aims to help characterize lung inflammation. With further validation, this approach could potentially assist in identifying or monitoring patients for targeted biologic therapies.

Shares of bioAffinity Technologies fell 17.46% to $3.90 following the announcement. Investors will watch for future clinical validation, as the test remains investigational, is not cleared or approved by the U.S. Food and Drug Administration, and is unavailable for clinical or diagnostic use.

Key points

  • bioAffinity Technologies will present research on its sputum-based lung inflammation test at CHEST 2026.
  • The test detected protein biomarkers including TSLP, CRLF2, IL4-Rα, and IL-5 tied to asthma and COPD drug targets.
  • Research expands on the CyPath Lung flow cytometry and artificial intelligence platform to identify targets for biologic therapies.
  • The investigational test is not cleared or approved by the FDA and cannot be used for clinical diagnosis.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What data will bioAffinity Technologies present at CHEST 2026?

The company will present data showing its investigational sputum test detects lung inflammation protein biomarkers linked to asthma and COPD drug targets.

Is bioAffinity Technologies' sputum test FDA approved?

No, the test is investigational, has not been cleared or approved by the FDA, and is not available for clinical or diagnostic use.

Which biomarkers does bioAffinity Technologies' test detect?

The test measures cellular and soluble biomarkers in sputum, including TSLP, CRLF2, IL4-Rα, and IL-5.